Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ELTX 
Elicio Therapeutics Inc. (ELTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: ELTX (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 101.79% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 154.89M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 2 | Beta 2.12 | 52 Weeks Range 4.05 - 12.62 | Updated Date 10/21/2025 |
52 Weeks Range 4.05 - 12.62 | Updated Date 10/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.98 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -123.26% | Return on Equity (TTM) -60013.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 173678803 | Price to Sales(TTM) - |
Enterprise Value 173678803 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.61 | Shares Outstanding 16338284 | Shares Floating 10640361 |
Shares Outstanding 16338284 | Shares Floating 10640361 | ||
Percent Insiders 39.36 | Percent Institutions 9.68 |
Upturn AI SWOT
Elicio Therapeutics Inc.
Company Overview
History and Background
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The company was founded to develop immunotherapies. It went public in 2023 via a SPAC merger.
Core Business Areas
- Amphiphile (AMP) Platform: Elicio Therapeutics is focused on developing AMP technologies for cancer immunotherapies and infectious diseases.
Leadership and Structure
The leadership team includes individuals with experience in biotechnology and drug development. The company has a board of directors and a management team overseeing its operations.
Top Products and Market Share
Key Offerings
- ELI-002 2P: An investigational AMP-modified KRAS vaccine targeting multiple KRAS mutations in patients with solid tumors. It is currently in clinical trials. Market share data is unavailable at this stage of development. Competitors in the KRAS vaccine space include companies like Mirati Therapeutics (MRTX) and Amgen (AMGN) (who acquired MRTX) who target specific KRAS mutations and other companies developing broad cancer vaccines.
- ELI-004 7P: An investigational AMP-modified mKRAS vaccine targeting multiple mKRAS mutations in patients with solid tumors, to be used in combination with Pembrolizumab. It is currently in clinical trials. Market share data is unavailable at this stage of development. Competitors in the mKRAS vaccine space include companies like Mirati Therapeutics (MRTX) and Amgen (AMGN) (who acquired MRTX) who target specific KRAS mutations and other companies developing broad cancer vaccines.
Market Dynamics
Industry Overview
The biotechnology industry, particularly the immuno-oncology segment, is experiencing significant growth driven by advancements in cancer therapies. The market is competitive, with many companies developing novel approaches to treat cancer.
Positioning
Elicio Therapeutics is positioned as an immunotherapy company focusing on the AMP platform to enhance immune responses. Its competitive advantage lies in its novel AMP technology, which aims to improve the delivery and efficacy of immunotherapies.
Total Addressable Market (TAM)
The TAM for cancer immunotherapies is substantial, estimated to be in the tens of billions of dollars annually. Elicio is positioned to capture a portion of this market with its AMP platform.
Upturn SWOT Analysis
Strengths
- Novel AMP technology platform
- Experienced leadership team
- Proprietary delivery system
- Clinical-stage pipeline
Weaknesses
- Limited clinical data
- Dependence on AMP platform success
- Relatively small company size
- Reliance on funding to advance clinical programs
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of AMP platform to other disease areas
- Positive clinical trial results
- Growing market for cancer immunotherapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Funding challenges
Competitors and Market Share
Key Competitors
- MRTX
- BMY
- GILD
Competitive Landscape
Elicio's AMP technology offers a competitive advantage in enhancing immune responses. However, it faces strong competition from larger companies with greater resources and established market presence. Companies in Immuno-Oncology such as Merck, Roche, GSK and others have great influence in this market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the recent IPO.
Future Projections: Future growth depends on the success of its clinical trials and partnerships. Analyst estimates are necessary for projections.
Recent Initiatives: Recent initiatives include advancing clinical trials for ELI-002 2P and ELI-004 7P and exploring collaborations.
Summary
Elicio Therapeutics is a clinical-stage biotechnology company with a novel AMP technology platform, offering potential in cancer immunotherapy. Its success hinges on positive clinical trial results and strategic partnerships. The company faces risks associated with clinical development, regulatory approvals, and competition from established players. Continued monitoring of clinical progress and financial health is essential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Press Releases
- Analyst Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data are estimations and may vary. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elicio Therapeutics Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-02-05 | CEO, President & Director Mr. Robert T. Connelly | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://elicio.com |
Full time employees 32 | Website https://elicio.com | ||
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node"targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.